6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
6-K: Colletion of Recent Announcements
6-K: Colletion of Recent Announcements
6-K: Sanofi Completes Acquisition of Inhibrx, Inc
6-K: Colletion of Recent Announcements
SANOFI | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
No Data